On Feb. 8, 2021, Oxford Immunotec announced it had entered into an MOU with Green Cross Medical to market the research use only T-SPOT Discovery SARS-CoV-2 kit in South Korea. The T-SPOT technology was the only globally approved ELISPOT used clinically for the diagnosis of Tuberculosis infection; the T-SPOT Discovery SARS-CoV-2 kit was available for research use across Europe and the U.S.